GSK PLC on Wednesday celebrated positive results from the first-ever efficacy trial of its preventative shingles treatment, Shingrix, in China.

According to the London-based pharmaceutical maker, results from a post-license phase IV trial showed 100% vaccine efficacy in the prevention of shingles in adults aged 50 and over in China.

No cases of shingles were reported among the participants who received Shingrix.

Data came from the first efficacy trial of Shingrix in China, which included almost 6,000 participants. No cases of shingles were reported among the participants who received the recombinant zoster vaccine (otherwise known as Shingrix) compared to 31 cases in the placebo arm.

‘The trial further demonstrates RZV’s efficacy in preventing herpes zoster in adults aged 50 and over irrespective of sex, geographic region and ancestry/ethnicity,’ said GSK.

Results from this phase IV trial will be submitted for publication in a peer-reviewed scientific journal later this year.

GSK shares were up 0.7% at 1,366.20 pence each in London on Wednesday morning.

Copyright 2023 Alliance News Ltd. All Rights Reserved.